Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15461665 | 0.96 | PDK2 (0.34) | GRM2ALOX5APFEN1S1PR1S1PR3 | |
| SCHEMBL13002205 | 0.94 | ALOX5AP (0.34) | GRM2ALOX5APFEN1S1PR1S1PR3 | |
| SCHEMBL13002343 | 0.94 | ALOX5AP (0.38) | GRM2ALOX5APFEN1S1PR1S1PR3 | |
| SCHEMBL12205424 | 0.93 | RARB (0.37) | GRM2ALOX5APFEN1S1PR1S1PR3 | |
| SCHEMBL3439584 | 0.93 | GRM2 (0.36) | GRM2ALOX5APFEN1S1PR1S1PR3 | |
| SCHEMBL3439575 | 0.92 | PDK2 (0.32) | GRM2S1PR1S1PR3PDK2 | |
| SCHEMBL12226099 | 0.92 | RARB (0.41) | GRM2ALOX5APFEN1S1PR1S1PR3 | |
| SCHEMBL13002339 | 0.92 | GRM2 (0.33) | GRM2ALOX5APFEN1S1PR1S1PR3 | |
| SCHEMBL15304006 | 0.92 | GRM2 (0.36) | GRM2ALOX5APFEN1S1PR1S1PR3 | |
| SCHEMBL15304009 | 0.92 | GRM2 (0.36) | GRM2ALOX5APFEN1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551359-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8551359-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8551359-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| EP-2377909-B1 | Liquid crystalline compounds and liquid crystalline media | MERCK PATENT GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2377909-B1 | Liquid crystalline compounds and liquid crystalline media | MERCK PATENT GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | Merck Patent Gesellschaft mit bescrankter Haftung (DE) | 2011-10-20 | — | — | US | disclosed |
| EP-2377909-A1 | Liquid crystalline compounds and liquid crystalline media | Merck Patent GmbH (DE) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110253935-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | CFB, CFD, LCT | GRM2 2881/4885ALOX5AP 1014/4885FEN1 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.